Brian Kennedy

Background

Brian Kennedy is Distinguished Professor at the National University of Singapore (NUS) and was president and CEO of the Buck Institute for Research on Aging from 2010 to 2016.

Lines of work

• mTOR biology and rapamycin — mechanistic and translational studies.
• Alpha-ketoglutarate (AKG) — identified as a metabolite that extends mouse lifespan and improves healthspan; commercial supplement (Rejuvant) trials in humans.
• Combination interventions — rather than single drugs.
• Asia-focused longevity — aging in Asian populations, Singapore as a geroscience hub.

Influence

Kennedy is one of the central translational voices for moving aging interventions from rodent models into well-designed human trials, and for combination thinking (multiple modest-effect interventions rather than a single “magic bullet”).

Contributions

• Buck Institute: former president; extended the Institute's scope and profile.
• National University of Singapore: current leadership at the Centre for Healthy Longevity; brings a translational focus.
• Rapamycin longevity research: one of the field's most vocal advocates for exploring rapamycin's clinical potential.
• PEARL trial collaboration: rapamycin-in-healthy-adults safety and biomarker signal.

Style

Combines molecular gerontology with clinical translation; particularly effective at bridging preclinical rapamycin biology with the human-dosing conversation.

Related entries

Rapamycin, PEARL trial, mTOR.

More on this topic

• Matt Kaeberlein — Researcher.
• resTORbio (Historic) — Company.
• Rapamycin vs Metformin (for Longevity) — Comparison.
• Rapamycin vs Senolytics — Comparison.
• Senomorphic — Concept.

Related entries

Rapamycin, mTOR, PEARL trial.